Oseltamivir and baloxavir: Dual treatment for rapidly developing ARDS on a patient with renal disease

Vega, Pool Tobar; Caldeira, Elena; Abad, Hasan; Saad, Peguy; LaChance, Erik

doi:10.1016/j.idcr.2020.e00819

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, when co-administered with oseltamivir, synergistic properties were shown between the two drugs. Moreover, resistance and drug-drug interactions were avoided [87][88][89]. Additionally, a recent study showed a lack of drug-drug interactions between baloxavir and NA inhibitors, though it failed to report improved clinical outcomes when compared to treatment plans consisting of a single antiviral [90].…”

Section: Cap-dependent Endonuclease Inhibitorsmentioning

confidence: 99%

Popular Influenza Antiviral Drugs: Mechanisms, Efficacy, and Resistance

Ley

2023

BioSci Rev.

View full text Add to dashboard Cite

Influenza viruses cause acute respiratory infections responsible for significant mortality and morbidity around the world. Various factors, such as antigenic drift, allow influenza strains to avoid being fully suppressed by seasonal vaccines. This has led to the increased scrutiny of antivirals as treatment and prophylaxis options for seasonal outbreaks and potential pandemics. Unfortunately, many influenza antivirals suffer from a lack of adequate clinical trials, as well as a lack of toxicity data. This is especially true of umifenovir (arbidol), a drug popularly used for the prevention and treatment of influenza strains in China and Russia. Neuraminidase inhibitors, though widely prescribed, display a potential for future resistance. Adamantanes, while proven to be effective in treating influenza A, are already encountering rapid and widespread cross-resistance and are effectively obsolete. Baloxavir marboxil, a newer antiviral, shows promise in treating acute uncomplicated influenza and may avoid the development of resistance when co-administered with other antiviral drugs. Indeed, the low genetic barrier to resistance associated with influenza antivirals could potentially be overcome by co-administration with other antivirals. This review explores the most widely prescribed antivirals for influenza treatment, their mechanisms of action, and the data currently available about their susceptibility to resistance and efficacy.

show abstract

Section: Cap-dependent Endonuclease Inhibitorsmentioning

confidence: 99%